Relmada Therapeutics EBIT

As of the most recent data (June 2026), RLMD shows a EBIT of $-63M. That compares with $-71M in the prior-year period — up 10.3% year over year. That is below the Consumer Discretionary sector average of $150B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RLMD's EBIT is now $-63M (was $-71M) — a 10.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Relmada Therapeutics is outperforming or lagging.

The Consumer Discretionary sector average EBIT is about $150B. Relmada Therapeutics is at $-63M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how RLMD stacks up against individual peers as well.

Tracking RLMD's ebit over time shows whether Relmada Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-63M That compares with $-71M in the prior-year period — up 10.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Relmada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-63M) with ownership activity and broader fundamentals.